In AGS gastric carcinoma cells, 5 μM amonafide increased the high-DNA-content/G2-M fraction after 24 h (P < .05 versus vehicle), which the authors interpreted as G2 arrest. [2]
Amonafide acetylation depends on NAT2 phenotype. In engineered RKO and DLD-1 colorectal cancer cells exposed to 10 μM amonafide for 30 min, rapid NAT2 clones showed higher acetylation velocity than slow NAT2 clones. This metabolic result should be distinguished from cytotoxic potency. [3]
Sequence-selective topoisomerase II-mediated DNA cleavage
Biochemical assay · Purified murine P388-derived topoisomerase II and an end-labeled pBR322 DNA fragment [1]
Amonafide produced a cleavage pattern distinct from other Topo II-active comparators in a purified-enzyme assay. The experiment supports stimulation of enzyme-mediated DNA cleavage; it does not measure a binding affinity or an inhibitory IC50.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1, 10 and 50 μM (Figure 2 amonafide lanes)
- Exposure duration
- 30 min at 37°C
- Method
- Cell-free DNA cleavage assay; DNA-only and enzyme-only lanes present
- Reported limits
- Drug stock solvent and replicate count not specified in the reviewed locations.
Methods and source locations
Compound reported in the paper: Amonafide; Compound label in the paper: amonafide
Parent amonafide literature result; salt/lot equivalence is not established.
p. 224 Materials and DNA cleavage reaction; p. 225 Figure 2 and Results: High site selectivity of amonafide stimulation of topoisomerase II DNA cleavage
Topoisomerase II-mediated pBR322 DNA cleavage: Denaturing polyacrylamide gel analysis — p. 224 Materials and DNA cleavage reaction; p. 225 Figure 2 and Results: High site selectivity of amonafide stimulation of topoisomerase II DNA cleavage
AGS cell-cycle response
Cell-based study · Human AGS gastric carcinoma cells [2]
After 24 h, amonafide at 5 μM significantly increased the high-DNA-content/G2-M fraction relative to vehicle. The authors interpret this as G2 arrest. The DNA-content assay alone does not distinguish G2 from mitosis.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1.25, 2.5 and 5 μM displayed in Figure 1C; significant effect reported at 5 μM
- Exposure duration
- 24 h
- Method
- Treatment followed by DNA-content flow cytometry
- Vehicle
- 1% DMSO (Figure 1 legend)
- Reported limits
- No numeric phase percentages extracted from the plot; no dose recommendation inferred.
Methods and source locations
Compound reported in the paper: Amonafide; Compound label in the paper: AMN
Parent amonafide literature result; salt/lot equivalence is not established.
Figure 1C and legend; Methods: MTT Assay (DNA-content assay paragraph); Results: AMN, AN, and MEAN Share Similar In Vitro Growth Inhibition and Apoptotic Properties
Increase in high-DNA-content/G2-M fraction relative to vehicle: DNA-content flow cytometry; one-way ANOVA with Dunnett test. Figure legend specifies SD from three or more independent experiments. — Figure 1C and legend; Methods: MTT Assay (DNA-content assay paragraph); Results: AMN, AN, and MEAN Share Similar In Vitro Growth Inhibition and Apoptotic Properties
NAT2-dependent amonafide acetylation
Cell-based study · Human RKO and DLD-1 colorectal cancer cells expressing rapid NAT2*13A or slow NAT2*6A; parental and vector controls [3]
Rapid NAT2 clones acetylated amonafide faster than slow NAT2 clones in a cell-based LC-MS/MS assay. The original figure also tests procainamide as a separate substrate; it is not an amonafide combination treatment.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM
- Exposure duration
- 30 min before quenching
- Method
- Cell-based acetylation assay with LC-MS/MS detection of amonafide and N-acetyl-amonafide
- Reported limits
- Stock solvent, salt and lot/catalog number not specified in this assay section; absolute velocity values were not estimated from bars.
Methods and source locations
Compound reported in the paper: Amonafide; Compound label in the paper: amonafide
Parent amonafide literature result; salt/lot equivalence is not established.
Results: Discovery of compounds selectively toxic to slow NAT2 cells (Sec4, paragraph beginning We reasoned); Figure 2a–d and legend; Methods: Quantification of NAT2 catalytic activity in cell lysates (Sec13)
Acetylation velocity in rapid versus slow NAT2 clones: LC-MS/MS; Figure 2c,d shows means of two independent experiments. P values are from Results text; no amonafide-specific statistical test is identified there. — Results: Discovery of compounds selectively toxic to slow NAT2 cells (Sec4, paragraph beginning We reasoned); Figure 2a–d and legend; Methods: Quantification of NAT2 catalytic activity in cell lysates (Sec13)